The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
 
Elisabetta Malangone-Monaco
Employment - IBM
Research Funding - AstraZeneca
 
Weiyan Li
Employment - AstraZeneca; AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Virginia Noxon
Employment - IBM
Research Funding - AstraZeneca (Inst)
 
Shan Jiang
Employment - Bayer; Merck
 
Suvina Amin
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Sameer Ghate
Employment - Merck Sharp & Dohme; Novartis
Stock and Other Ownership Interests - Advaxis (I); Bellicum Pharmaceuticals (I); Bellicum Pharmaceuticals (I); Calithera Biosciences (I); Idera (I); Mannkind; Provectus
 
Umang Swami
Consulting or Advisory Role - Seagen
Research Funding - Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)